

Off-patent biologicals and biosimilars tendering in Europe – a proposal towards more sustainable practices

Pharmaceuticals – Biosimilars special issue

Liese Barbier, Steven Simoens, Caroline Soontjens, Barbara Claus, Arnold G. Vulto, Isabelle Huys

Corresponding author: Liese Barbier, Email: liese.barbier@kuleuven.be

Supp. Table S1. Survey participants' characteristics			
Characteristics	Participants		N =
	N	%	
In which country do you work?			60
Belgium	11	18	
Bulgaria	3	5	
Croatia	1	2	
Cyprus	1	2	
Czech Republic	1	2	
Denmark	1	2	
France	2	3	
Finland	2	3	
Germany	1	2	
Ireland	1	2	
Italy	1	2	
Latvia	1	2	
Malta	3	5	
Netherlands	2	3	
Norway	5	8	
Poland	3	5	
Portugal	7	12	
Romania	3	5	
Slovakia	3	5	
Slovenia	1	2	
Spain	4	7	
Sweden	1	2	
UK	2	3	
In which type of institution do you work?			60
<i>Multiple answers possible</i>			
Hospital pharmacy	40	67	
Hospital procurement unit	4	7	
Health insurance company	1	2	
National purchasing group	4	7	
3 rd party payer	1	2	
Regional purchasing group	5	8	
National healthcare authority/Ministry of health	6	10	
Public health service	1	2	
University	12	20	
Other	5	8	
Please indicate if you work in a(n)...*			42
Academic hospital	18	43	

Off-patent biologicals and biosimilars tendering in Europe

Regional hospital	20	48
Other	4	10
Please indicate if you work in a(n)...*		42
Public hospital	34	81
Private hospital	6	14
Other	2	5
<i>*For participants who work in a hospital</i>		
<i>Abbreviations: N: number</i>		